.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,148,207

« Back to Dashboard

Claims for Patent: 7,148,207

Title:Oral fludara of high-purity formulation with quick release of active ingredient
Abstract:This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
Inventor(s): Heil; Wolfgang (Stelle, DE), Tistam; Ulf (Wezembeek Oppem, BE), Lipp; Ralph (Berlin, DE), Tack; Johannes-Wilhelm (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:10/324,141
Patent Claims: 1. A quick-release tablet formulation that comprises 1 to 100 mg of the active ingredient fludarabine phosphate having a purity of >99.19%, lactose monohydrate, colloidal silicon dioxide, microcrystalline cellulose, sodium carboxymethyl cellulose, and magnesium stearate, wherein said formulation releases fludarabine phosphate with a quick release profile, and wherein the contaminants in the fludarabine-phosphate do not exceed: 0.02% 2-fluoro-9-(.beta.-D-arabinofuranosyl)-9H-purine-6-amine, 0.12% 6-amino-9(5-O-phosphono-.beta.-D-arabinofuranosyl)-9H-purin-2-ol, 0.02% 2-fluoro-9H-purine-6-amine, 0.02% 6-amino-9H-purin-2-ol, 0.05% 2-fluoro-9-(5-O-phosphono-.beta.-D-ribofuranosyl)-9H-purine-6-amine, 0.1% 9-(3,5-O-diphosphono-.beta.-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amin- e, 0.1% 9-(2,5-O-diphosphono-.beta.-D-arabinofuranosyl)-2-fluoro-9H-purine- -6-amine, 0.02% 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-9H-purine-6-amine, 0.06% 2-ethoxy-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-9H-purine-6-am- ine, 0.02% 2-(6-amino-9H-purin-2-yl)-9-(5-O-phosphono-.beta.-D-arabinofura- nosyl)- 9H-purine-6-amine and O,O'-bis[2-(6-amino-2-fluoro-9H-purin-9-yl)-5-deoxy-.alpha.-D- arabinofuranos-5-yl]-phosphate, 0.1% 9-(2-chloro-2-deoxy-5-phosphono-.beta.-D-arabinofuranosyl)-2-fluoro-9H-pu- rine- 6-amine, and 0.1% 9-(2,5-anhydro-.beta.-D-arabinofuranosyl)-2-fluoro-9H-purine-6-amine.

2. A quick-release tablet formulation according to claim 1, which comprises 1 70 mg of the active ingredient fludarabine phosphate having a purity of >99.19%, 50 100 mg of lactose monohydrate, 0.1 5 mg of colloidal silicon dioxide, 40 100 mg of microcrystalline cellulose, 1 10 mg of sodium carboxymethyl cellulose and 0.5 10 mg of magnesium stearate.

3. A quick-release tablet formulation according to claim 1, which comprises 1 50 mg of the active ingredient fludarabine phosphate having a purity of >99.19%, 60 90 mg of lactose monohydrate, 0.5 1 mg of colloidal silicon dioxide, 50 90 mg of microcrystalline cellulose, 2.5 5 mg of sodium carboxymethyl cellulose and 1 3 mg of magnesium stearate.

4. A quick-release tablet formulation according to claim 1, which comprises 10 mg of the active ingredient fludarabine phosphate having a purity of >99.19%, 74.75 mg of lactose monohydrate, 0.75 mg of colloidal silicon dioxide, 60.00 mg of microcrystalline cellulose, 3.00 mg of sodium carboxymethyl cellulose and 1.5 2.00 mg of magnesium stearate.

5. A quick-release tablet formulation according to claim 1, which comprises the active ingredient fludarabine phosphate having a purity of >99.37%.

6. A quick-release tablet formulation according to claim 1, which comprises the active ingredient fludarabine phosphate having a purity of >99.57%.

7. A quick-release tablet formulation according to claim 1, which comprises the active ingredient fludarabine phosphate having a purity of >99.80%.

8. A quick-release tablet formulation according to claim 1, which comprises the active ingredient fludarabine phosphate having a purity of >99.85%.

9. A quick-release tablet formulation according to claim 1, wherein the tablet has a core encased by a coating comprising: 1 5 mg of hydroxypropyl methyl cellulose, 0.1 1 mg of talc, 0.1 5 mg of titanium dioxide, 0.01 0.1 mg of yellow iron oxide pigment and 0.01 0.1 mg of red iron oxide pigment.

10. A quick-release tablet formulation according to claim 1, wherein the tablet has a core encased by a coating, comprising: 1 3 mg of hydroxypropyl methyl cellulose, 0.1 0.8 mg of talc, 0.1 2 mg of titanium dioxide, 0.01 0.05 mg of yellow iron oxide pigment and 0.01 0.05 mg of red iron oxide pigment.

11. A quick-release tablet formulation according to claim 1, wherein the tablet has a core encased by a coating, comprising: 2.250 mg of hydroxypropyl methyl cellulose, 0.450 mg of talc, 1.187 mg of titanium dioxide, 0.036 mg of yellow iron oxide pigment and 0.036 mg of red iron oxide pigment.

12. A medication for treating cancer comprising a tablet formulation according to claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc